Return to Results

A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Dose-Comparison Study to Determine the Efficacy and Safety of BG00012 in Subjects with Relapsing-Remitting Multiple Sclerosis

new search

Trial Conditions
  • Multiple Sclerosis
What is the purpose of this trial?

The purpose of this study is to find out if treatment with BG00012 can decrease the number of MS relapses during a certain time period. Other goals of the study are to find out if, over time, BG00012 treatment can decrease the number of certain types of brain lesions commonly seen in MS patients and slow down the time it takes for your disease to get worse. The safety of BG00012, how well you tolerate it, and the effect it may have on tests and evaluations used to assess MS are also goals of the study.

Date & Status



 Some of the criteria for this study require the patient to be between 18-55, have a diagnosis of relapsing-remitting MS, and to have had at least one relapse in the past year.

Steward Physician(s)
  • St. Elizabeth's Medical Center - Recruiting
For more information about this trial, contact

Nina Perkins
Phone: 617-789-3171

Physician Researcher

Physician Name/s:

  • Ellen S. Lathi MD
  • Other Information

    Sponsor: Biogen Idec, Inc.
    Phase: Phase 3
    Trial ID: 00404
    Volunteers:  Not Accepting Healthy Volunteers

    new search

    Connect with Steward

    Visit Our Twitter Feed Visit Our Facebook Page Email This Page Print This Page

    Subscribe to our patient e-newsletter

    Copyright © 2015 Steward Health Care
    Connect Healthcare Panacea CMS Solutions